APA (7th ed.) Citation

Zannad, F., Alla, F., Dousset, B., & Pitt, B. (2000). Limitation of the excessive extracellular matrix turnover is a major determinant of the beneficial effect of spironolactone on survival in patients with CHF: Insights from the RALES trial. European Journal of Heart Failure, 2(S1), 98. https://doi.org/10.1016/S1388-9842(00)80350-5

Chicago Style (17th ed.) Citation

Zannad, F., F. Alla, B. Dousset, and B. Pitt. "Limitation of the Excessive Extracellular Matrix Turnover Is a Major Determinant of the Beneficial Effect of Spironolactone on Survival in Patients with CHF: Insights from the RALES Trial." European Journal of Heart Failure 2, no. S1 (2000): 98. https://doi.org/10.1016/S1388-9842(00)80350-5.

MLA (9th ed.) Citation

Zannad, F., et al. "Limitation of the Excessive Extracellular Matrix Turnover Is a Major Determinant of the Beneficial Effect of Spironolactone on Survival in Patients with CHF: Insights from the RALES Trial." European Journal of Heart Failure, vol. 2, no. S1, 2000, p. 98, https://doi.org/10.1016/S1388-9842(00)80350-5.